Please use this identifier to cite or link to this item:
|SHARE CORE BASE|
|Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE|
Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment
|Authors:||Milanés-Guisado, Yusnelkis CSIC; Gutiérrez Valencia, Alicia CSIC ORCID; Trujillo-Rodríguez, María CSIC; Espinosa, Nuria CSIC ORCID; Viciana, Pompeyo CSIC; López-Cortés, Luis F. CSIC||Issue Date:||22-Oct-2018||Publisher:||Public Library of Science||Citation:||PLoS ONE 13(10): e0205777 (2018)||Abstract:||[Objectives] To analyse the correlation and concordance between aCD4, CD4%, CD4/CD8, their intra-patient variability, and to compare the immune recovery (IR) rates based on the three parameters in HIV-infected patients after starting antiretroviral therapy.
[Methods] From a prospectively followed cohort, patients who maintained HIV-RNA suppression in ≥95% of the determinations throughout the follow-up were selected. IR was defined as aCD4 >650/μl, CD4% ≥38% or CD4/CD8 ≥1.
[Results] A total of 1164 patients with a median follow-up of 5 years were analysed. The increases in aCD4, CD4% and CD4/CD8 were highest during the first year and considerably lower thereafter regardless of baseline aCD4. The annual increases in aCD4 showed poor correlations with those of CD4% (r = 0.143–0.250) and CD4/CD8 (r = 0.101–0.192) but were high between CD4% and CD4/CD8 (r = 0.765–0.844; p<0.001). The median intra-annual coefficients of variation for aCD4, CD4/CD8 and CD4% were 12.5, 8.5 and 6.6, respectively. After five years, 66.7%, 41.6% and 42.1% of the patients reached aCD4 >650/μl, CD4% ≥38%, and CD4/CD8 ≥1, respectively, while only 31% achieved both aCD4 and CD4/CD8 target values.
[Conclusions] The increases in aCD4 poorly correlate with those of CD4% and CD4/CD8. IR rates based on aCD4 significantly overstate those obtained by CD4% and CD4/CD8. CD4% and CD4/CD8 are more stable markers than aCD4 and should be taken into account to monitor the IR after treatment initiation.
|Publisher version (URL):||https://doi.org/10.1371/journal.pone.0205777||URI:||http://hdl.handle.net/10261/178479||DOI:||10.1371/journal.pone.0205777||E-ISSN:||1932-6203|
|Appears in Collections:||(IBIS) Artículos|
Show full item record
Files in This Item:
|art_cell_count_overstate_Milanes.pdf||1,08 MB||Adobe PDF|
Review this work
checked on Mar 25, 2023
checked on Mar 23, 2023
WEB OF SCIENCETM
checked on Mar 22, 2023
checked on Mar 29, 2023
checked on Mar 29, 2023
This item is licensed under a Creative Commons License